154 related articles for article (PubMed ID: 31498180)
1. Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors.
Jain V; Venigalla S; Reddy VK; Lukens JN; Mitchell TC; Shabason JE
J Immunother; 2020 Jan; 43(1):8-15. PubMed ID: 31498180
[TBL] [Abstract][Full Text] [Related]
2. Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma.
Jain V; Venigalla S; Sebro RA; Karakousis GC; Wilson RJ; Weber KL; Shabason JE
Cancer Med; 2019 Oct; 8(14):6295-6304. PubMed ID: 31483578
[TBL] [Abstract][Full Text] [Related]
3. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
Moyers JT; Patel A; Shih W; Nagaraj G
JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
[TBL] [Abstract][Full Text] [Related]
4. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.
Dobry AS; Zogg CK; Hodi FS; Smith TR; Ott PA; Iorgulescu JB
Cancer Immunol Immunother; 2018 Dec; 67(12):1833-1844. PubMed ID: 30191256
[TBL] [Abstract][Full Text] [Related]
5. Use of immunotherapy and surgery for stage IV melanoma.
Molina G; Kasumova GG; Qadan M; Boland GM
Cancer; 2020 Jun; 126(11):2614-2624. PubMed ID: 32157676
[TBL] [Abstract][Full Text] [Related]
6. Association of Receipt of Systemic Treatment for Melanoma With Insurance Type in North Carolina.
Adamson AS; Jackson BE; Baggett CD; Thomas NE; Haynes AB; Pignone MP
Med Care; 2023 Dec; 61(12):829-835. PubMed ID: 37708348
[TBL] [Abstract][Full Text] [Related]
7. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.
Halpern MT; Ward EM; Pavluck AL; Schrag NM; Bian J; Chen AY
Lancet Oncol; 2008 Mar; 9(3):222-31. PubMed ID: 18282806
[TBL] [Abstract][Full Text] [Related]
8. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-PD-1 Era.
Lamba N; Ott PA; Iorgulescu JB
JAMA Netw Open; 2022 Aug; 5(8):e2225459. PubMed ID: 36006646
[TBL] [Abstract][Full Text] [Related]
9. Association of health insurance with outcomes in adults ages 18 to 64 years with melanoma in the United States.
Amini A; Rusthoven CG; Waxweiler TV; Jones BL; Fisher CM; Karam SD; Raben D
J Am Acad Dermatol; 2016 Feb; 74(2):309-16. PubMed ID: 26670715
[TBL] [Abstract][Full Text] [Related]
10. Management of metastatic melanoma in Texas: disparities in the utilization of immunotherapy following the regulatory approval of immune checkpoint inhibitors.
Olateju OA; Zeng Z; Thornton JD; Mgbere O; Essien EJ
BMC Cancer; 2023 Jul; 23(1):655. PubMed ID: 37442992
[TBL] [Abstract][Full Text] [Related]
11. Medicaid and Uninsured Hepatocellular Carcinoma Patients Have More Advanced Tumor Stage and Are Less Likely to Receive Treatment.
Wang J; Ha J; Lopez A; Bhuket T; Liu B; Wong RJ
J Clin Gastroenterol; 2018; 52(5):437-443. PubMed ID: 28723861
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.
Sussman TA; Knackstedt R; Wei W; Funchain P; Gastman BR
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35998982
[TBL] [Abstract][Full Text] [Related]
13. Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.
Haque W; Verma V; Butler EB; Teh BS
J Immunother; 2019; 42(6):228-235. PubMed ID: 30985445
[TBL] [Abstract][Full Text] [Related]
14. Surgical Utilization and Outcomes for Patients with Stage IV Melanoma in the Modern Immunotherapy Era.
Lwin TM; Kaelberer Z; Ruan M; Molina G; Boland G
Ann Surg Oncol; 2023 Aug; 30(8):5005-5012. PubMed ID: 37121988
[TBL] [Abstract][Full Text] [Related]
15. Impact of insurance status on receipt of definitive surgical therapy and posttreatment outcomes in early stage lung cancer.
Stokes SM; Wakeam E; Swords DS; Stringham JR; Varghese TK
Surgery; 2018 Dec; 164(6):1287-1293. PubMed ID: 30170821
[TBL] [Abstract][Full Text] [Related]
16. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
Perry AM; Brunner AM; Zou T; McGregor KL; Amrein PC; Hobbs GS; Ballen KK; Neuberg DS; Fathi AT
Cancer; 2017 Jul; 123(13):2561-2569. PubMed ID: 28464280
[TBL] [Abstract][Full Text] [Related]
17. Association Between Primary Payer Status and Survival in Patients With Stage III Colon Cancer: An National Cancer Database Analysis.
Ahmed A; Tahseen A; England E; Wolfe K; Simhachalam M; Homan T; Sitenga J; Walters RW; Silberstein PT
Clin Colorectal Cancer; 2019 Mar; 18(1):e1-e7. PubMed ID: 30297265
[TBL] [Abstract][Full Text] [Related]
18. Health Insurance Affects Head and Neck Cancer Treatment Patterns and Outcomes.
Inverso G; Mahal BA; Aizer AA; Donoff RB; Chuang SK
J Oral Maxillofac Surg; 2016 Jun; 74(6):1241-7. PubMed ID: 26851312
[TBL] [Abstract][Full Text] [Related]
19. Insurance Status Effect on Laryngeal Cancer Survival: A Population Based Study.
Abt NB; Miller LE; Parikh A; Bhattacharyya N
Ann Otol Rhinol Laryngol; 2022 Jul; 131(7):775-781. PubMed ID: 34486418
[TBL] [Abstract][Full Text] [Related]
20. Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors.
Markt SC; Lago-Hernandez CA; Miller RE; Mahal BA; Bernard B; Albiges L; Frazier LA; Beard CJ; Wright AA; Sweeney CJ
Cancer; 2016 Oct; 122(20):3127-3135. PubMed ID: 27500561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
